Introduction
Cardiomyopathy in childhood, mitochondrial dysfunction, and the role of L-carnitine
Mitochondrial defects in cardiomyopathy and neuromuscular disease
Design and implementation of the North American Pediatric Cardiomyopathy Registry
Familial carnitine transporter defect: A treatable cause of cardiomyopathy in children
Increased glycolytic substrate protection improves ischemic cardiac dysfunction and reduces injury
Regulation of carbohydrate metabolism in ischemia and reperfusion
Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration
Myocardial infarction and left ventricular remodeling: Results of the CEDIM trial